IFNG and systemic sclerosis: Other uncontrolled case series and literature reviews suggested that IVIg were associated with: (i) a decrease in mRSS in SSc10–12; (ii) an increase in IFNγ in the skin of SSc patients; (iii) a corticosteroid-sparing benefit in SSc-associated myopathy, without any effect on the skin in this disease13.